Periscope Capital’s NKGen Biotech, Inc. Warrants NKGNW Stock Holding History

Periscope Capital’s Portfolio NKGNW Stock Details NKGNW Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q3	–	Sell	-19,110	Closed	-$1.89K	–	295
2024 Q2	$1.89K	Sell	19,110 -48,500	-72%	-$5.07K	﹤0.01%	314
2024 Q1	$9.68K	Sell	67,610 -24,700	-27%	-$2.81K	﹤0.01%	349
2023 Q4	$7.46K	Sell	92,310 -27,490	-23%	-$3.71K	﹤0.01%	407
2023 Q3	$47.3K	Hold	119,800	–	–	0.01%	376
2023 Q2	$25K	Hold	119,800	–	–	﹤0.01%	530
2023 Q1	$16.8K	Hold	119,800	–	–	﹤0.01%	672
2022 Q4	$10.2K	Hold	119,800	–	–	﹤0.01%	764
2022 Q3	$18K	Hold	119,800	–	–	﹤0.01%	899
2022 Q2	$31K	Hold	119,800	–	–	﹤0.01%	807
2022 Q1	$73K	Hold	119,800	–	–	﹤0.01%	843
2021 Q4	$137K	Buy	+119,800	New	+$122K	﹤0.01%	765

Other funds holding NKGNW

RCM

Rivernorth Capital Management West Palm Beach, Florida $2B AUM 0.66% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

BNP Paribas Financial Markets Paris, France $206B AUM 31.61% 1-Year Est. Return

Balyasny Asset Management Chicago, Illinois $77.1B AUM 42.89% 1-Year Est. Return

SCM

Shaolin Capital Management Miami, Florida $2.71B AUM 64.83% 1-Year Est. Return

Jane Street New York $777B AUM 61.18% 1-Year Est. Return

Healthcare of Ontario Pension Plan (HOOPP) Trust Fund Toronto, Ontario, Canada $62.2B AUM 31.35% 1-Year Est. Return

EAM

Exos Asset Management New York $2.32K AUM 108.13% 1-Year Est. Return

CAC

Cowen and Company New York $2.97B AUM 105.26% 1-Year Est. Return

TCA

Taconic Capital Advisors New York $229M AUM 110.07% 1-Year Est. Return

Periscope Capital's NKGNW Position: Q3 2024 in Review

Periscope Capital sold out of NKGen Biotech, Inc. Warrants (NKGNW) in Q3 2024, closing a stake of 19,110 shares — an estimated $1.89K sold.

Periscope Capital first reported a position in NKGNW in Q4 2021 and held it in 11 quarters. The position peaked at $137K in Q4 2021. 29 funds tracked by Wall St. Rank hold NKGNW as of Q3 2024.

Periscope Capital reported no remaining NKGen Biotech, Inc. Warrants position as of Q3 2024 after selling out during the quarter.
Periscope Capital sold 19,110 NKGen Biotech, Inc. Warrants shares in Q3 2024, an estimated $1.89K.
Periscope Capital first reported a position in NKGen Biotech, Inc. Warrants in Q4 2021 and held it in 11 quarters.
Periscope Capital's NKGen Biotech, Inc. Warrants position peaked at $137K in Q4 2021.
29 funds tracked by Wall St. Rank held NKGen Biotech, Inc. Warrants as of Q3 2024.

Based on Periscope Capital's 13F filing for Q3 2024, filed 12 Nov 2024.